Skip to main content

What the FDA labels say about taking them together

Clopidogrel and cobicistat

Cobicistat's FDA label of February 10, 2026 names clopidogrel in its drug interactions section; the clopidogrel label PlainMeds reads does not name cobicistat. The cobicistat label: “Coadministration with clopidogrel is not recommended due to potential reduction of the antiplatelet activity of clopidogrel.”

Check it at the source: the clopidogrel FDA label on DailyMed (effective May 30, 2025, Sanofi-Aventis U.S. LLC); the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.).

What does the clopidogrel label say about cobicistat?

Clopidogrel's label (effective May 30, 2025) does not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Plavix), Sanofi-Aventis U.S. LLC, effective May 30, 2025 (SPL set de8b0b67-eb25-4684-83b5-7ad785314227), via openFDA; the full label on DailyMed

What does the cobicistat label say about clopidogrel?

Cobicistat label, drug interactions

Concomitant Drug Class/Drug Name: clopidogrel; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↓ clopidogrel active metabolite; Clinical Comment: Coadministration with clopidogrel is not recommended due to potential reduction of the antiplatelet activity of clopidogrel.

Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

35Clopidogrel generic labelers
0Cobicistat generic labelers
ClopidogrelCobicistat
Labeled forHeart attack and coronary artery disease, AnginaHIV
Boxed warningYesNo
Pharmacy cost (NADAC)$0.0472 per tablet 75 mg tabletn/a
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?